{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-034175","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2025-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.988547+00:00","generated_at":"2026-05-25T07:13:02.532559+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MindMed reports $273.7M cash, advances MM120 Phase 3 trials in GAD and MDD","bullets":["Cash and equivalents $273.7M at Dec 31, 2024 vs $99.7M a year ago; raised ~$250M in 2024.","Q4 2024 R&D expense $21.8M (from $11.5M); full-year $65.3M (from $52.1M).","Phase 3 Voyage (GAD) dosing initiated; topline data expected 1H 2026.","Phase 3 Panorama (GAD) initiated Q1 2025; data expected 2H 2026.","On track to start Phase 3 Emerge (MDD) 1H 2025; topline data 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-034175","json":"https://secwatch.observer/filing/0000950170-25-034175.json","markdown":"https://secwatch.observer/filing/0000950170-25-034175.md","text":"https://secwatch.observer/filing/0000950170-25-034175.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025034175/0000950170-25-034175-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025034175/mnmd-20250306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T07:13:02.532559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}